Longitudinal patterns of inflammatory mediators after acute HIV infection correlate to intact and total reservoir

Front Immunol. 2024 Jan 5:14:1337316. doi: 10.3389/fimmu.2023.1337316. eCollection 2023.

Abstract

Background: Despite the beneficial effects of antiretroviral therapy (ART) initiation during acute HIV infection (AHI), residual immune activation remains a hallmark of treated HIV infection.

Methods: Plasma concentrations of 40 mediators were measured longitudinally in 39 early treated participants of a Belgian AHI cohort (HIV+) and in 21 HIV-negative controls (HIV-). We investigated the association of the inflammatory profile with clinical presentation, plasma viral load, immunological parameters, and in-depth characterization of the HIV reservoir.

Results: While levels of most soluble mediators normalized with suppressive ART, we demonstrated the persistence of a pro-inflammatory signature in early treated HIV+ participants in comparison to HIV- controls. Examination of these mediators demonstrated a correlation with their levels during AHI, which seemed to be viremia-driven, and suggested involvement of an activated myeloid compartment, IFN-γ-signaling, and inflammasome-related pathways. Interestingly, some of these pro-inflammatory mediators correlated with a larger reservoir size and slower reservoir decay. In contrast, we also identified soluble mediators which were associated with favorable effects on immunovirological outcomes and reservoir, both during and after AHI.

Conclusion: These data highlight how the persistent pro-inflammatory profile observed in early ART treated individuals is shaped during AHI and is intertwined with viral dynamics.

Keywords: HIV reservoir; acute HIV infection; chemokines; cytokines; early ART; inflammation; plasma soluble mediators.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cognition
  • HIV Infections* / drug therapy
  • Humans
  • Inflammasomes
  • Inflammation Mediators*
  • Plasma

Substances

  • Inflammation Mediators
  • Inflammasomes

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. JDC is a beneficiary of a Ghent University Special Research Fund (BOF) doctoral scholarship (BOF19/DOC/220). LV was supported by the Research Foundation Flanders (1.8.020.09.N.00) and the Collen-Francqui Research Professor Mandate (STIDI62018000101). The project was funded by the Ghent University Special Research Fund (BOF.DOC.2019.0068.02). The multicentric sample collection was supported by ViiV Healthcare and the Belgium Research on AIDS and HIV Consortium (BREACH).